TCMS for the Treatment of Foot Pain Caused By Diabetic Neuropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03596203|
Recruitment Status : Not yet recruiting
First Posted : July 23, 2018
Last Update Posted : July 23, 2018
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Neuropathies||Device: TransCutaneous Magnetic Stimulator (TCMS)||Phase 1|
The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse will relieve foot pain from Diabetic Neuropathy (DN). The United States Food and Drug Administration (FDA) has approved a similar device for treatment of migraine headaches, but this type of device has not been studied for the treatment of DN. No significant adverse reactions or side effects have been reported from the use of magnetic stimulation for the headache treatment. Some patients who have migraine headaches have excellent pain relief with the magnetic treatment even if they did not get pain relief using medications.
The investigators do not know whether this magnetic treatment will relieve the foot pain caused by diabetic neuropathy, so they will test this by applying 50 strong magnet pulses to the painful area of each foot. This procedure will be repeated onto three parts of each foot. First onto the bottom of the foot, then the top of the foot and then the back of the foot including a portion of the ankle. The effect on pain in each foot while walking for about 10 steps will be recorded before the study begins and periodically for 28 days. This testing will provide data as to any improvement in pain relief. If the participants' reported pain is reduced as a result of the magnetic treatment, then the magnetic pulses will have shown that they have reduced the pain. Additional studies will be needed to further investigate this treatment and to determine how to obtain statistically significant data as to whether this therapy reduces the foot pain caused by diabetic neuropathy.
One side effect of this treatment may be some muscular jerking of the foot or the leg during the application of the magnetic pulses. This jerking will last only during the treatment and will not be painful or harmful.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||TransCutaneous Magnetic Stimulation (TCMS) for the Treatment of Foot Pain Caused By Diabetic Neuropathy|
|Estimated Study Start Date :||October 1, 2018|
|Estimated Primary Completion Date :||July 30, 2019|
|Estimated Study Completion Date :||December 1, 2019|
|Experimental: Treatment group||
Device: TransCutaneous Magnetic Stimulator (TCMS)
TCMS coils which are connected to feet and pulse generator. The generator will then be turned on to deliver 50 pulses at a pulse period of 6 seconds and at a pulse intensity of 100% to the bottom of the foot with the TCMS coil.
- Pain level [ Time Frame: 1 to 28 days ]Numeric Pain Rating Scale, 0-10 with 0 being no pain, and 10 being worst pain ever experienced
- Functional status and Patient satisfaction with treatment [ Time Frame: 1 to 28 days ]Descriptive Questionnaire to asses whether participant has improved functional status, such as ability to walk and whether participant is satisfied with treatment
- Changes in pain medication [ Time Frame: 1 to 28 days ]Assessment of pain medications taken by participant prior to treatment and 28 days after treatment to deteremine if any of pain medications were increased, decreased or eliminated after treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03596203
|Contact: Medha Satyarengga, M.D.||443-682-6873||MSatyarengga@som.umaryland.edu|
|Contact: Kashif Munir|
|United States, Maryland|
|University of Maryland Center for Diabetes and Endocrinology||Not yet recruiting|
|Baltimore, Maryland, United States, 21201|
|Contact: Medha Satyarengga, M.D. 443-682-6873|
|Principal Investigator:||Kashif Munir, M.D.||University of Maryland|